MX340094B - Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. - Google Patents

Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento.

Info

Publication number
MX340094B
MX340094B MX2013004960A MX2013004960A MX340094B MX 340094 B MX340094 B MX 340094B MX 2013004960 A MX2013004960 A MX 2013004960A MX 2013004960 A MX2013004960 A MX 2013004960A MX 340094 B MX340094 B MX 340094B
Authority
MX
Mexico
Prior art keywords
complement
complement activation
individual
point
lateral flow
Prior art date
Application number
MX2013004960A
Other languages
English (en)
Other versions
MX2013004960A (es
Inventor
Olson Paul
Moss Don
Original Assignee
Kypha Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kypha Inc filed Critical Kypha Inc
Publication of MX2013004960A publication Critical patent/MX2013004960A/es
Publication of MX340094B publication Critical patent/MX340094B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Abstract

La presente invención se refiere a un inmunoensayo de flujo lateral para la detección de punto de cuidado de un marcador de la activación del complemento en una muestra de fluido corporal que comprende proteínas del complemento, el inmunoensayo de flujo lateral está caracterizado porque comprende: una tira de membrana; un anticuerpo de detección que se une a un primer epítopo del marcador; una línea de prueba que comprende un anticuerpo de captura que se une a un segundo epítopo del marcador; y una línea de control que comprende un anticuerpo que se une a un analito de control, en donde el marcador se selecciona del grupo que consiste en C3 intacto y iC3b.
MX2013004960A 2010-11-02 2011-11-02 Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. MX340094B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40929710P 2010-11-02 2010-11-02
PCT/US2011/058945 WO2012071145A1 (en) 2010-11-02 2011-11-02 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Publications (2)

Publication Number Publication Date
MX2013004960A MX2013004960A (es) 2013-12-16
MX340094B true MX340094B (es) 2016-06-27

Family

ID=46146161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004960A MX340094B (es) 2010-11-02 2011-11-02 Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento.

Country Status (8)

Country Link
US (2) US9182396B2 (es)
EP (2) EP3095876A1 (es)
JP (1) JP5859557B2 (es)
AU (2) AU2011332241B2 (es)
CA (1) CA2816423A1 (es)
ES (1) ES2564290T3 (es)
MX (1) MX340094B (es)
WO (1) WO2012071145A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071145A1 (en) 2010-11-02 2012-05-31 Kypha, Inc. Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
US8865164B2 (en) * 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
JP6053927B2 (ja) * 2013-06-10 2016-12-27 旭化成株式会社 イムノクロマト診断キット
WO2015168615A2 (en) * 2014-05-02 2015-11-05 Uab Research Foundation Methods and compositions for diagnosis and treatment of meningitis
US11029318B2 (en) * 2015-08-28 2021-06-08 Kypha, Inc. Methods for predicting and treating patients with increased risk of adverse pregnancy outcome
KR102141591B1 (ko) * 2016-05-13 2020-09-14 광주과학기술원 진단용 키트
JP7331000B2 (ja) * 2018-03-26 2023-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ３転換酵素のプロテアーゼ活性を測定するためのスループットの高い方法
EP3581934A1 (en) * 2018-06-14 2019-12-18 Otto-von-Guericke-Universität Magdeburg Complement factors for diagnosis of low-grade infections in a human subject
WO2021222169A1 (en) * 2020-04-27 2021-11-04 Zinselmeyer Bernd H Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2
CN116806312A (zh) * 2021-01-26 2023-09-26 积水医疗株式会社 免疫学测定方法
WO2023192436A1 (en) * 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
JPS595958B2 (ja) 1975-12-30 1984-02-08 トウキヨウケイソウ カブシキガイシヤ 変量測定・伝送装置
EP0097440B1 (en) * 1982-06-14 1986-09-24 The Upjohn Company Method and kit for removing and assaying complement system fragments
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
SE452067B (sv) 1986-04-11 1987-11-09 Ulf R Nilsson Reagens for och sett vid immunkemisk bestemning av c3a
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
WO2003062824A1 (en) * 2002-01-23 2003-07-31 Boditech Inc. Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor
WO2004093636A2 (en) * 2003-04-17 2004-11-04 Rauno Joks PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY
ZA200510325B (en) 2003-06-13 2008-04-30 Univ Pittsburgh Monitoring immunologic, hematologic and inflammatory diseases
EP1687636B1 (en) 2003-09-29 2009-01-14 PEAS Institut AB Rapid determination of different forms of hepatocyte growth factor (hgf) in the body fluids
WO2005078442A1 (en) * 2004-02-10 2005-08-25 Dantini Daniel C Comprehensive food allergy test
US20060292700A1 (en) * 2005-06-22 2006-12-28 Naishu Wang Diffused interrupted lateral flow immunoassay device and method
WO2006124888A2 (en) * 2005-05-16 2006-11-23 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
US7910381B2 (en) 2005-10-13 2011-03-22 BioAssay Works Immuno gold lateral flow assay
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
WO2010009206A2 (en) * 2008-07-15 2010-01-21 Rapid Pathogen Screening, Inc. In situ lysis of cells in lateral flow immunoassays
US20110251099A1 (en) * 2008-12-30 2011-10-13 Sudha Visvanathan SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
US9291622B2 (en) * 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
WO2012071145A1 (en) * 2010-11-02 2012-05-31 Kypha, Inc. Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Also Published As

Publication number Publication date
WO2012071145A1 (en) 2012-05-31
US9182396B2 (en) 2015-11-10
AU2011332241A1 (en) 2013-05-23
AU2016200772B2 (en) 2018-02-01
US20120141457A1 (en) 2012-06-07
MX2013004960A (es) 2013-12-16
AU2011332241B2 (en) 2015-11-26
CA2816423A1 (en) 2012-05-31
EP2635702A4 (en) 2014-04-02
EP3095876A1 (en) 2016-11-23
JP5859557B2 (ja) 2016-02-10
AU2016200772A1 (en) 2016-02-25
US9939446B2 (en) 2018-04-10
EP2635702B1 (en) 2016-02-03
ES2564290T3 (es) 2016-03-21
EP2635702A1 (en) 2013-09-11
JP2014502347A (ja) 2014-01-30
US20150346211A1 (en) 2015-12-03
AU2011332241A2 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
MX2013004960A (es) Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de transtornos asociados con el complemento.
WO2014150817A3 (en) Method and system to predict response to treatments for mental disorders
MX2016006252A (es) Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono.
MX340824B (es) Metodos para monitorear fluidos dentro de o producidos desde una formacion subterranea utilizando dispositivos optico-analiticos.
NZ608208A (en) Breast cancer diagnostics
GB2504022A (en) Surface preparation
WO2015102726A3 (en) A microfluidic device for real-time clinical monitoring and quantitative assessment of whole blood coagulation
GB2484631A (en) System and methods for monitoring a well
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2023002021A (es) Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.
IN2014KN02809A (es)
MY190476A (en) Steady state fluid flow verification for sample takeoff
WO2012068040A3 (en) Detection of vestibular disorders based on vestibular noise
GB2544922A (en) Methods and systems for simulating a hydrocarbon field using a multi-point well connection method
WO2014141293A3 (en) A method and system for estimation of blood anylates
EA201290828A1 (ru) Устройство и способ контроля частиц
EA201791707A1 (ru) Переносное устройство для оперативного измерения концентрации сероводорода в выходящем газовом потоке
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
GB2538374A (en) Determining formation gas composition during well drilling
UA78641U (ru) Способ прогнозирования тяжести больных острым панкреатитом
EP3502271A3 (en) Blood biomarkers for appendicitis and diagnostics methods using biomarkers
WO2013050950A3 (en) Method for monitoring, diagnosis and/or prognosis of hypoxia related disorders using nfat5
WO2014009055A9 (en) Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene.
WO2013136059A3 (en) Biomarker, uses thereof and therapy
UA62320U (ru) Способ диагностики состояния микроциркуляции крови в норме и патологии

Legal Events

Date Code Title Description
FG Grant or registration